Gastrointestinal Cancer News

Society for Immunotherapy of Cancer announced its 2020 fellowship and award recipients.

Tumor rupture appeared associated with shorter OS among patients treated with or without imatinib after surgery for gastrointestinal stromal tumors, or GIST, according to results of a post-hoc observational study published in JAMA Surgery.

The COVID-19 pandemic will result in nearly 10,000 additional deaths due to breast cancer and colorectal cancer over the next decade, according to NCI projections.

Glenn D. Steele Jr., MD, PhD, has been elected chair of City of Hope’s board of directors.

The FDA granted fast track designation to fruquintinib for treatment of certain patients with metastatic colorectal cancer.

The FDA granted fast track designation to liposomal irinotecan as part of a first-line combination for the treatment of adults with previously untreated, unresectable, locally advanced and metastatic pancreatic ductal adenocarcinoma.

The FDA approved a second biomarker-based indication for the anti-PD-1 therapy pembrolizumab.

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.

NantKwest and ImmunityBio have partnered on a phase 2 trial to examine the efficacy and safety of a chemoimmunotherapy regimen for treatment of metastatic or locally advanced pancreatic cancer.

The FDA granted orphan drug designation to DKN-01 for the treatment of gastric or gastroesophageal junction cancers.